S-1: Cardiff Lexington Files S-1 for Nasdaq Uplisting, Reports Mixed Financials

Cardiff Lexington Corporation files an S-1 registration statement for a common stock offering, contingent on a Nasdaq Capital Market uplisting, amidst recurring operating losses and an extended accounts receivable cycle.

Summary

• Cardiff Lexington Corporation is a healthcare holding company focused on acquiring and building niche health clinics in orthopedics, spine care, and pain management, operating primarily through its Nova Ortho and Spine, LLC subsidiary.
• The company also owns Edge View Properties, Inc., a real estate company with vacant land holdings, which management expects to eventually sell.
• Revenue for the nine months ended September 30, 2025, increased by 70.18% to $8,763,314 compared to $5,149,416 for the same period in 2024, primarily due to increased office visits and surgical procedures.
• However, the company reported a net loss of $2,821,471 for the nine months ended September 30, 2025, an increase from a net loss of $2,392,657 for the same period in 2024.
• For the year ended December 31, 2024, revenue decreased by 30.23% to $8,270,126 from $11,853,266 in 2023, attributed to lower settlement realization rates, a shift to lower-revenue pain management treatments, and hurricane impacts.
• The company incurred a net loss of $3,302,999 for the year ended December 31, 2024, a significant decline from a net income of $3,028,394 in 2023.
• An independent registered public accounting firm included a going concern explanatory paragraph in its report, citing recurring operating losses and an accumulated deficit of $76,533,799 as of September 30, 2025.
• The company's business model, focusing on uninsured patients involved in lawsuits, results in an extended accounts receivable collection period of 18 to 24 months, creating liquidity and bad debt risks.
• The settlement realization rate for accounts receivable decreased from a historical 49% to 44% in 2024, and further to 42% as of September 30, 2025, due to efforts to accelerate cash settlements by accepting lower amounts.
• The S-1 filing is for a public offering of common stock, contingent upon the company's uplisting to The Nasdaq Capital Market under the symbol CDIX.
• Net proceeds from the offering are intended for debt repayment, working capital, and general corporate purposes, including future acquisitions.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including recurring losses, a substantial accumulated deficit, and a going concern warning from auditors. While revenue growth in the most recent nine-month period is positive, it follows a significant decline in the prior year, and overall profitability remains elusive. The extended accounts receivable cycle and lack of systematic processes add operational risk. The planned Nasdaq uplisting and capital raise are critical but uncertain, and dilution for new investors will be substantial. The overall financial health is weak, despite strategic growth ambitions.

Positives

• Revenue for the nine months ended September 30, 2025, increased significantly by 70.18% to $8,763,314, driven by higher office visits and surgical procedures.
• The company has a targeted acquisition strategy focused on middle-market niche healthcare clinics with strong organic growth plans and cash generation.
• Management possesses extensive executive, investment, and operational experience in the healthcare sector, along with a broad network for sourcing acquisition opportunities.
• The public company structure is seen as a competitive advantage for attracting acquisition targets by offering increased access to funding and equity incentives for management.
• The healthcare business model, focusing on plaintiff-related care, is partially insulated from declining reimbursement programs of Medicare/Medicaid and traditional health insurance.
• The company's twelve healthcare facilities are estimated to be operating at 35% capacity as of September 30, 2025, indicating significant organic growth potential.
• The company has a focus on clinical excellence, rigorous recruiting, and continuous professional development for its healthcare staff.
• The revolving purchase and security agreement with DML HC Series, LLC was increased to a maximum advance amount of $23,000,000, providing enhanced liquidity.

Negatives

• The company has sustained recurring operating losses since its inception, with a net loss of $2,821,471 for the nine months ended September 30, 2025, and $3,302,999 for the year ended December 31, 2024.
• An accumulated deficit of $76,533,799 as of September 30, 2025, raises substantial doubt about the company's ability to continue as a going concern.
• The typical accounts receivable collection lifecycle is between 18 and 24 months, creating significant liquidity and cash flow constraints, and increasing exposure to bad debt.
• The company lacks systematic processes and resources to effectively manage the aging of its accounts receivables, leading to inefficiencies and higher operational costs, and expects significant expenditures to remedy this.
• The settlement realization rate for gross billed charges decreased from a historical 49% to 44% in 2024, and further to 42% as of September 30, 2025, due to efforts to accelerate cash settlements by accepting lower amounts.
• Cash balance significantly decreased to $232,033 as of September 30, 2025, from $1,188,185 at December 31, 2024.
• Total liabilities increased substantially to $22,596,065 as of September 30, 2025, from $16,324,405 at December 31, 2024.
• The company's future operations and acquisition strategy are dependent on obtaining additional financing, with no assurance of availability or acceptable terms.
• The market price of common stock has been highly volatile, with significant declines in recent quarters (e.g., from $412.50 high in Q1 2023 to $0.55 low in Q4 2025).

Risks

• The report of the independent registered public accounting firm included a going concern explanatory paragraph, indicating substantial doubt about the company's ability to continue operations.
• The typical accounts receivable collection lifecycle of 18 to 24 months creates liquidity and cash flow constraints, increased exposure to bad debt, dependence on external financing, and negative impacts on financial metrics.
• Lack of systematic processes and resources to support the aging of accounts receivables can result in inefficiencies, higher operational costs, and potential inaccuracies in financial reporting, requiring significant future expenditures.
• The acquisition strategy exposes the company to substantial risks, including failure to identify material problems during due diligence, overpaying for assets, difficulty in retaining customers, and challenges in integrating acquired businesses.
• Failure to manage a growing and changing business could have a material adverse effect on business, prospects, financial condition, and results of operations.
• Competition for businesses fitting the acquisition strategy may lead to acquiring targets at sub-optimal prices or foregoing opportunities.
• Inability to successfully fund acquisitions due to unavailability of equity or debt financing on acceptable terms could impede the acquisition strategy.
• Future success is dependent on the management teams of acquired businesses, and the loss of key personnel could materially adversely affect financial condition and operations.
• Engaging in business transactions with target businesses that have relationships with executive officers or directors may create conflicts of interest.
• Operational objectives and business plans of subsidiaries may conflict with the company's overall objectives, creating competing demands for resources.
• If the company ceases to control and operate its businesses or engages in certain investment-related activities, it may be deemed an investment company under the Investment Company Act, leading to additional regulation and costs.
• Material weaknesses in internal control over financial reporting could lead to inaccurate financial results, fraud, and loss of investor confidence.
• Ability to grow through organic expansion is dependent on many factors, including adequate working capital, facility quality, physician recruitment, and market demand.
• Changes to payment rates or methods of third-party payors, including government healthcare programs, or changes in payor mix, could adversely affect operating margins and revenues.
• An increase in uninsured or underinsured patients or deterioration in collectability of accounts could harm results of operations.
• Failure to timely or accurately bill for services could negatively impact net revenue and cash flow.
• Competition for patients from other healthcare providers, including tax-supported or non-profit entities with greater resources, could lead to a decline in patient volume.
• Dependence on ability to recruit and retain quality physicians, nurses, and medical support staff, with staffing shortages potentially increasing labor costs and harming operations.
• Failure to comply with extensive healthcare laws and government regulations (e.g., False Claims Act, HIPAA, anti-kickback statute, Stark Law) could result in civil or criminal penalties, or require significant operational changes.
• Loss of accreditation for existing facilities or failure to receive accreditation for new facilities could render them ineligible for Medicare or Medicaid reimbursement.
• Exposure to lawsuits, including medical malpractice and professional liability claims, for which the company may not be fully reserved, could harm business value and reputation.
• Demand fluctuations in the real estate industry, adverse weather conditions, natural disasters, and unforeseen planning/environmental issues could negatively impact the real estate business.
• Decreases in the market value of real estate investments could reduce results of operations.
• Changes in tax laws, taxes, or fees may increase the cost of development or sale of real estate property.
• Potential environmental liabilities with respect to real estate assets, including remediation costs that could exceed property value.
• Uninsured losses relating to real property or excessively expensive insurance premiums may adversely affect stock value.
• Limited trading in common stock prior to the offering, and no assurance of an active market developing or being sustained on Nasdaq, could lead to price volatility and difficulty in reselling shares.
• The market price of common stock may be highly volatile due to factors beyond the company's control, including speculative trading and lack of profits.
• Failure to maintain Nasdaq listing standards could result in delisting, impairing stockholders' ability to trade and raising capital.
• Officers and directors own a significant percentage of voting securities, potentially reducing minority stockholders' ability to effect corporate actions.
• The company could become a controlled company under Nasdaq rules, potentially exempting it from certain corporate governance requirements.
• Management has broad discretion over the use of net proceeds from the offering, which may not yield significant returns.
• No current plans to pay cash dividends on common stock for the foreseeable future, meaning investors may only receive a return through stock appreciation.
• Immediate and substantial dilution for new investors as the offering price is significantly higher than the pro forma net tangible book value per share.
• Future issuances of common stock or convertible securities, or expiration of lock-up agreements, could cause the market price to decline and dilute holdings.
• Rule 144 sales in the future may have a depressive effect on the stock price.
• Future issuances of debt or preferred stock could rank senior to common stock, adversely affecting returns.
• If common stock becomes subject to penny stock rules, it would become more difficult to trade shares.
• Lack of research reports from securities industry analysts or unfavorable reports could negatively affect market price and trading volume.
• Anti-takeover provisions in charter documents and Nevada law could make an acquisition more difficult and limit stockholder attempts to replace management.
• Investment in the company may involve complex tax implications, and investors are urged to consult their own advisors.

Future Outlook

Management believes that current working capital and expected additional financing should be sufficient to fund operations and satisfy obligations for at least one year. However, additional funds from new financing and/or future equity raises are required for continued operations and to execute the business plan, particularly for acquiring additional businesses, with an estimated need of $5 million to $10 million in outside capital. The company intends to continue its acquisition and value creation strategy in the healthcare sector, focusing on outpatient Orthopedic Surgery Centers and related Clinics in eighteen identified states. Efforts to enhance operational efficiencies and productivity, including improved scheduling, use of mid-level providers, and leadership training, are ongoing. The company will continue to evaluate and update its settlement realization rate estimates quarterly.

Management Comments

• Management believes, based on our operating plan, that current working capital and current and expected additional financing should be sufficient to fund operations and satisfy our obligations as they come due for at least one year.
• Management does not currently have any plans to develop this property (Edge View real estate) and expects to eventually sell the property.
• We believe that the most important factors relating to the overall utilization of a facility include adequate working capital, the quality and market position of the facility and the number, quality and specialties of physicians providing patient care within the facility.
• We believe that our processes related to managed care contracting, billing, coding, collection and compliance have driven a strong track record of efficient revenue cycle management.

Industry Context

The healthcare sector is highly competitive, with increasing competition among providers due to regulatory and technological changes, managed care systems, cost containment pressures, and a shift towards outpatient treatment. The market for healthcare acquisitions is fragmented, presenting opportunities for Cardiff Lexington. The company's focus on plaintiff-related care partially insulates it from declining Medicare/Medicaid and traditional health insurance reimbursements. However, the industry faces challenges such as a nationwide shortage of nurses and clinical staff, which can increase labor costs.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess performance against global benchmarks. Therefore, a direct comparison to industry standards is not possible based solely on the provided information.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently aware of any legal proceedings or claims that it believes will have a material adverse effect on its business, financial condition, or operating results.

Related Party Transactions

• Short-term advances from Daniel Thompson, Chairman of the Board, totaling $120,997 as of December 31, 2023, were non-interest bearing and due on demand, and were fully repaid during the year ended December 31, 2024.
• Amounts due to previous owners of Edge View Properties, Inc., who are current managers, total $4,979 as of September 30, 2025, and December 31, 2024; these amounts are due on demand and do not bear interest.
• A twelve-month convertible promissory note in the principal amount of $5,000 was issued to CEO Alex Cunningham on August 25, 2023, for operating expenses, bearing 10% interest per annum, and was paid in full in August 2024.
• Employment agreements with Alex Cunningham (CEO) and Daniel Thompson (Chairman) include base salaries, annual bonuses, and performance bonuses tied to Nasdaq listing and acquisitions, with provisions for compensation conversion to promissory notes if cash payment is not possible.
• Accrued compensation for Alex Cunningham and Daniel Thompson totaled $2,215,500 and $2,320,500, respectively, as of September 30, 2025, included in accrued expenses related parties.
• On January 19, 2024, 62,500 shares of series I preferred stock were issued to Daniel R. Thompson and Alex Cunningham each for $250,000 bonus compensation for fiscal year 2023.

Stakeholder Impact

• **Shareholders:** Face significant dilution from the public offering and potential future equity raises. The going concern warning and recurring losses indicate high investment risk. The concentration of voting power among officers and directors could limit minority shareholder influence. The lack of current plans for cash dividends means returns depend solely on stock appreciation.
• **Employees:** The company's growth strategy and potential capital raise could lead to expansion and new opportunities. Equity incentive plans are in place to align management and employee interests with stockholders. However, the company's financial instability and need for cost reductions could pose risks to job security or compensation if funds are not raised.
• **Customers (Patients):** The focus on plaintiff-related care for uninsured patients means services are provided without immediate payment, which could be beneficial for patients. However, the company's financial health and operational challenges in accounts receivable management could indirectly affect service quality or availability if not adequately addressed.
• **Suppliers/Creditors:** The extended accounts receivable cycle and reliance on external financing, coupled with recurring losses, could pose risks to timely payments for suppliers and the recoverability of loans for creditors. The increase in the line of credit facility provides some short-term liquidity but also increases overall debt exposure.

Next Steps

• Complete the public offering of common stock.
• Achieve uplisting of common stock to The Nasdaq Capital Market.
• Repay certain debt using net proceeds from the offering.
• Utilize net proceeds for working capital and general corporate purposes.
• Pursue future acquisitions of orthopedic and related modality practices, particularly outpatient Orthopedic Surgery Centers and Clinics in identified states.
• Implement enhanced practices to better capture and manage the aging of accounts receivables.
• Continue efforts to improve operational efficiencies and productivity at healthcare facilities, including scheduling, mid-level provider utilization, and compensation programs.
• Regularly review and update the estimate of settlement realization rates for accounts receivable on a quarterly basis.

Key Dates

Recommendation

Cardiff Lexington Corporation presents a high-risk investment profile. The company has a history of recurring operating losses and a substantial accumulated deficit, leading to a 'going concern' explanatory paragraph from its auditors. Its business model relies on an extremely long accounts receivable collection cycle (18-24 months) for uninsured patients, which severely strains liquidity and cash flow, and has led to a declining settlement realization rate (from 49% to 42%). While the company aims for a Nasdaq uplisting and a capital raise, these are contingent and uncertain. The significant dilution for new investors, coupled with the company's weak financial position, makes it a speculative investment. The current financial instability and operational challenges outweigh the potential for future growth through acquisitions, making a 'sell' recommendation prudent for risk-averse investors.

Keywords

Healthcare, Orthopedics, Spine Care, Pain Management, Medical Clinics, Acquisition Strategy, SEC Filing, S-1, Nasdaq Uplisting, Common Stock Offering, Accounts Receivable, Going Concern, Financial Performance, Nova Ortho and Spine, Edge View Properties, Convertible Preferred Stock, Capital Raise, Risk Factors, Corporate Governance, Nevada Corporation